Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy.
Fifty-four patients with diabetic peripheral neuropathy were treated with carbamazepine for a period of one year. Clinical assessment and nerve conduction velocity studies (NCV) were done periodically. Forty-nine patients had symptomatic relief of all sensory manifestations but NCV remained essentially unchanged. Untoward effects of the drug were frequent but transitory. It was concluded that carbamazepine is a dependable drug for the treatment of symptomatic diabetic sensory polyneuropathy.
D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction
D002220:Carbamazepine